title: Dermatomyositis and polymyositis: from immunopathology to immunotherapy (immunobiologics).
abstract: Idiopathic inflammatory myopathies (IIM), which include dermatomyositis (DM) and polymyositis (PM), are chronic systemic diseases associated with high morbidity and functional disability. Current treatment is based on the use of glucocorticoids and immunosuppressive drugs, but a considerable number of patients is refractory to traditional therapy. That has led to the attempted use of biologics based on the physiopathogenesis of IIM. From the immunopathological viewpoint, PM and DM differ: the former is more related to cellular immunity, while the latter, to humoral immunity. In both, however, elevated concentrations of proinflammatory interleukins (TNF, IL-1, IL-6) and increased expression of molecules related to costimulation of T lymphocytes have been described; thus, the use of biologics in those conditions seems reasonable. Considering the biologics available, open-label studies are scarce, comprising mainly case reports and series. TNF blockers have yielded conflicting results, with no evidence of good response to treatment. The anti-CD20 therapy has the most promising results. Data on T lymphocyte costimulation blockade and anti-IL-6 therapy are extremely scarce, preventing any consideration. Thus, the use of biologics in IIM still remains an unconquered frontier. Biologics may have an important role in the management of IIM refractory to conventional therapy, but further prospective studies based on objective parameters of response to treatment are needed. So far, anti-CD20 therapy seems to be the most promising treatment for refractory IIM.
authors.affiliation: Service of Rheumatology,, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Brazil. samuel.shinjo@gmail.com
authors.forename: Samuel Katsuyuki
authors.initials: SK
authors.lastname: Shinjo
authors.forename: Fernando Henrique Carlos
authors.initials: FH
authors.lastname: de Souza
authors.forename: Julio Cesar Bertacini
authors.initials: JC
authors.lastname: de Moraes
mesh_terms: D001691:Biological Therapy; D003882:Dermatomyositis / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D017285:Polymyositis / Q000276:immunology* / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D014409:Tumor Necrosis Factor-alpha